174 related articles for article (PubMed ID: 15341067)
21. Synthesis, characterization and antidiabetic properties of N(1)-2,4-dihydroxybenzylidene-N(4)-2-hydroxybenzylidene-S-methyl-thiosemicarbazidato-oxovanadium(IV).
Yanardag R; Demirci TB; Ulküseven B; Bolkent S; Tunali S; Bolkent S
Eur J Med Chem; 2009 Feb; 44(2):818-26. PubMed ID: 18621448
[TBL] [Abstract][Full Text] [Related]
22. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
23. Structure-dependent metallokinetics of antidiabetic vanadyl-picolinate complexes in rats: studies on solution structure, insulinomimetic activity, and metallokinetics.
Yasui H; Tamura A; Takino T; Sakurai H
J Inorg Biochem; 2002 Jul; 91(1):327-38. PubMed ID: 12121792
[TBL] [Abstract][Full Text] [Related]
24. [Vanadium compounds--a new class of therapeutic agents for the treatment of diabetes mellitus].
Beliaeva NF; Gorodetskiĭ VK; Tochilkin AI; Golubev MA; Semenova NV; Kovel'man IR
Vopr Med Khim; 2000; 46(4):344-60. PubMed ID: 11075417
[TBL] [Abstract][Full Text] [Related]
25. [Synthesis and hypoglycemic activity of bis(L-malato)oxovanadium(IV)].
Gorodetskiĭ VK; Tochilkin AI; Beliaeva NF; Kovel'man IR; Korovkin BF
Biomed Khim; 2011; 57(1):133-7. PubMed ID: 21516785
[TBL] [Abstract][Full Text] [Related]
26. A new halogenated antidiabetic vanadyl complex, bis(5-iodopicolinato)oxovanadium(IV): in vitro and in vivo insulinomimetic evaluations and metallokinetic analysis.
Takino T; Yasui H; Yoshitake A; Hamajima Y; Matsushita R; Takada J; Sakurai H
J Biol Inorg Chem; 2001 Feb; 6(2):133-42. PubMed ID: 11293406
[TBL] [Abstract][Full Text] [Related]
27. Bis(allixinato)oxovanadium(IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes.
Adachi Y; Yoshida J; Kodera Y; Katoh A; Takada J; Sakurai H
J Med Chem; 2006 Jun; 49(11):3251-6. PubMed ID: 16722643
[TBL] [Abstract][Full Text] [Related]
28. Streptozotocin-induced alterations in rat liver Golgi complexes are ameliorated by BMOV [Bis(maltolato)oxovanadium(IV)] activity.
Kordowiak AM; Dziga D; Dabroś W
Horm Metab Res; 2004 Mar; 36(3):148-54. PubMed ID: 15057667
[TBL] [Abstract][Full Text] [Related]
29. Organo-vanadium compounds are potent activators of the protein kinase B signaling pathway and protein tyrosine phosphorylation: mechanism of insulinomimesis.
Mehdi MZ; Srivastava AK
Arch Biochem Biophys; 2005 Aug; 440(2):158-64. PubMed ID: 16055077
[TBL] [Abstract][Full Text] [Related]
30. [Vanadium derivatives--a new source of antidiabetic drugs].
Dănilă G; Lupaşcu D
Rev Med Chir Soc Med Nat Iasi; 1999; 103(3-4):74-7. PubMed ID: 10756929
[TBL] [Abstract][Full Text] [Related]
31. Effect of glurenorm on immunohistochemical changes in pancreatic beta cells of rats in experimental diabetes.
Koyuturk M; Ozsoy-Sacan O; Bolkent S; Yanardag R
Indian J Exp Biol; 2005 Mar; 43(3):268-71. PubMed ID: 15816415
[TBL] [Abstract][Full Text] [Related]
32. Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes.
Zuo YQ; Liu WP; Niu YF; Tian CF; Xie MJ; Chen XZ; Li L
J Pharm Pharmacol; 2008 Oct; 60(10):1335-40. PubMed ID: 18812026
[TBL] [Abstract][Full Text] [Related]
33. Vanadyl sulfate protects against streptozotocin-induced morphological and biochemical changes in rat aorta.
Akgün-Dar K; Bolkent S; Yanardag R; Tunali S
Cell Biochem Funct; 2007; 25(6):603-9. PubMed ID: 16892454
[TBL] [Abstract][Full Text] [Related]
34. Effect of insulin-mimetic vanadyl sulfate on cytochrome P450 2E1-dependent p-nitrophenol hydroxylation in the liver microsomes of streptozotocin-induced type 1 diabetic rats.
Kataoka S; Yasui H; Hiromura M; Sakurai H
Life Sci; 2005 Oct; 77(22):2814-29. PubMed ID: 15964029
[TBL] [Abstract][Full Text] [Related]
35. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities.
Yamaguchi M; Wakasugi K; Saito R; Adachi Y; Yoshikawa Y; Sakurai H; Katoh A
J Inorg Biochem; 2006 Feb; 100(2):260-9. PubMed ID: 16387366
[TBL] [Abstract][Full Text] [Related]
36. Improvement of diabetic states in streptozotocin-induced type 1 diabetic rats by vanadyl sulfate in enteric-coated capsules.
Fugono J; Yasui H; Sakurai H
J Pharm Pharmacol; 2005 May; 57(5):665-9. PubMed ID: 15901357
[TBL] [Abstract][Full Text] [Related]
37. Anti-diabetic effects of sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate in streptozotocin-induced diabetic rats.
Li M; Smee JJ; Ding W; Crans DC
J Inorg Biochem; 2009 Apr; 103(4):585-9. PubMed ID: 19203797
[TBL] [Abstract][Full Text] [Related]
38. Novel vanadyl complexes with quinoxaline N(1),N(4)-dioxide derivatives as potent in vitro insulin-mimetic compounds.
Noblía P; Vieites M; Torre MH; Costa-Filho AJ; Cerecetto H; González M; Lavaggi ML; Adachi Y; Sakurai H; Gambino D
J Inorg Biochem; 2006 Feb; 100(2):281-7. PubMed ID: 16386797
[TBL] [Abstract][Full Text] [Related]
39. Reducing agents mitigate protein synthesis inhibition mediated by vanadate and vanadyl compounds in reticulocyte lysates.
Krishnamoorthy T; Sreedhara A; Rao CP; Ramaiah KV
Arch Biochem Biophys; 1998 Jan; 349(1):122-8. PubMed ID: 9439590
[TBL] [Abstract][Full Text] [Related]
40. Is the hypoglycemic action of vanadium compounds related to the suppression of feeding?
Huang M; Wu Y; Wang N; Wang Z; Zhao P; Yang X
Biol Trace Elem Res; 2014 Mar; 157(3):242-8. PubMed ID: 24446192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
